logo

For the Inventor, By the Inventor

Helsinki, Finland

Glykos Finland Oy

Calculating rank
USPTO Granted Patents = 30

% Expired Patents = 46.7


Forward Citations = 30

Loading Chart...
Loading Chart...

47 inventors (with patents filed for the assignee):

goldMedal Jari Natunen (21 out of 28 patents)

silverMedal Tero Satomaa (17 out of 18 patents)

bronzeMedal Juhani Saarinen (16 out of 17 patents)

4.  Anne Huuskonen (12 out of 15 patents)

5.  Markku Saloheimo (12 out of 25 patents)

6.  Anne Kanerva (11 out of 23 patents)

7.  Christopher Landowski (10 out of 11 patents)

8.  Ann Westerholm-Parvinen (10 out of 16 patents)

9.  Jukka Hiltunen (9 out of 11 patents)

10.  Annamari Heiskanen (8 out of 8 patents)

11.  Jari Helin (7 out of 13 patents)

12.  Heidi Anderson (7 out of 8 patents)

13.  Maria Blomqvist (7 out of 7 patents)

14.  Jarmo Laine (6 out of 8 patents)

15.  Taina Jaatinen (6 out of 6 patents)


Core Competencies:
Hydrophilic Linkers
Glycoprotein Conjugates
Toxic Payloads
Protease Deficient Cells
Filamentous Fungi
Fucosylated Glycoproteins
Tumor Specific Epitopes
Oligosaccharide Sequences
Carbohydrate Profiles
Culture Methods
Fusion Enzymes

30 patents:

1. 11793886 - Hydrophilic linkers and conjugates thereof (2023-10-24),
2. 11723983 - Conjugates of a glycoprotein or a glycan with a toxic payload (2023-08-15),
3. 11180767 - Protease deficient filamentous fungal cells and methods of use thereof (2021-11-23),
4. 10988791 - Multiple proteases deficient filamentous fungal cells and methods of use thereof (2021-04-27),
5. 10973922 - Glycoprotein-toxic payload conjugates (2021-04-13),
6. 10973920 - Saccharide derivative of a toxic payload and antibody conjugates thereof (2021-04-13),
7. 10731168 - Protease deficient filamentous fungal cells and methods of use thereof (2020-08-04),
8. 10724063 - Multiple proteases deficient filamentous fungal cells and methods of use thereof (2020-07-28),
9. 10724013 - O-mannosyltransferase deficient filamentous fungal cells and methods of use thereof (2020-07-28),
10. 10544440 - Multiple protease deficient filamentous fungal cells and methods of use thereof (2020-01-28),
11. 10513724 - Production of glycoproteins with mammalian-like N-glycans in filamentous fungi (2019-12-24),
12. 10435731 - Multiple proteases deficient filamentous fungal cells and methods of use thereof (2019-10-08),
13. 10240159 - Protease deficient filamentous fungal cells and methods of use thereof (2019-03-26),
14. 10000734 - Method for evaluating cell populations (2018-06-19),
15. 9695454 - Production of fucosylated glycoproteins (2017-07-04),
Company Overview
Glykos Finland Oy is a biotechnology company based in Helsinki, specializing in the development of innovative solutions for drug discovery and development. The company focuses on leveraging advanced biopharmaceutical technologies to enhance the efficiency of therapeutic development processes. Glykos is committed to addressing complex challenges in the pharmaceutical industry, utilizing its expertise in protein engineering and molecular biology to create impactful solutions that support the advancement of healthcare.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

30 Patents

#43 in Helsinki

#121 in Finland

#21,907 in the World

Helsinki, FI
Helsinki, Finland

Glykos Finland Oy

Forward Citations = 30

47 inventors:

goldMedal Jari Natunen (21 out of 28 patents)

silverMedal Tero Satomaa (17 out of 18 patents)

bronzeMedal Juhani Saarinen (16 out of 17 patents)

4.  Anne Huuskonen (12 out of 15 patents)

5.  Markku Saloheimo (12 out of 25 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Glykos Finland Oy. Retrieved from https://idiyas.com/company/glykos-finland-oy

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…